FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma

Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2‐[18 F] fluoro‐2‐deoxy‐D‐glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC.

[1]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells. , 1995, The Journal of Biological Chemistry.

[2]  T. Jones,et al.  Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.

[3]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.

[4]  S. Reske,et al.  Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  T Jones,et al.  In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas , 1983, Annals of neurology.

[6]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  R L Wahl,et al.  In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  K. Erlandsson,et al.  A new approach to three-dimensional image reconstruction in PET , 1991, Conference Record of the 1991 IEEE Nuclear Science Symposium and Medical Imaging Conference.

[9]  W. Vaalburg,et al.  Radiation-induced inhibition of tumor growth as monitored by PET using L-[1-11C]tyrosine and fluorine-18-fluorodeoxyglucose. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  K. Erlandsson,et al.  A PET system based on 2-18FDG production with a low energy electrostatic proton accelerator and a dual headed PET scanner. , 1992, Acta oncologica.

[11]  R. Wahl,et al.  Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. , 2000, Acta oncologica.

[12]  C. Bohm,et al.  Performance Study of the PC‐384 Positron Camera System for Emission Tomography of the Brain , 1984, Journal of computer assisted tomography.

[13]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Müller-Gärtner,et al.  Early changes in fluorine-18-FDG uptake during radiotherapy. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[16]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Minn,et al.  Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Giampietro Gasparini,et al.  Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .

[20]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[21]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[22]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[23]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  F Pozza,et al.  Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[26]  J. Hoffman,et al.  Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy , 1994, Head & neck.

[27]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[28]  H Evans,et al.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas , 2000, British Journal of Cancer.

[29]  K. Någren,et al.  Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  H. Minn,et al.  Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  K. Erlandsson,et al.  Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. , 1997, Acta oncologica.

[32]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Marsden,et al.  A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.